Literature DB >> 6373632

Behçet's disease.

R C Wong, C N Ellis, L A Diaz.   

Abstract

Behçet's disease is a multisystem disease featuring mucocutaneous, ocular, intestinal, articular, vascular, urogenital, and neurologic involvement. While classically intermittent in its manifestations, the disease can stabilize and become chronic in a given organ system. The diagnosis of Behçet's disease is based on clinical criteria. Recurrent aphthous ulcerations in the mouth, skin lesions, eye lesions, and genital ulcerations must be present during the course of the disease for a diagnosis of Behçet's disease to be made unequivocally. A nonspecific skin hyperreactivity called pathergy is said to be helpful in the diagnosis. There are no pathognomonic laboratory findings, but biopsy usually shows a venulitis. The pathogenesis of the disease is unknown. No virus has been satisfactorily isolated to date. There is evidence of an increased frequency of HLA-B5 and HLA-B12. Humoral and cellular immunity seem to play a major part in the pathogenesis of the various manifestations of the disease. The treatment of Behçet's disease is difficult to evaluate because of the many spontaneous exacerbations and remissions during the clinical course of the disease. Topical corticosteroids for orogenital ulcers and ocular inflammation are helpful. Intralesional injections for affected joints and retrobulbar tissues are useful in some cases. Systemic corticosteroids have appeared to be helpful for all manifestations of the disease. It is customary to use 60 mg of prednisone by mouth daily during acute exacerbations, then to taper as the condition improves. Chlorambucil has been shown to be safe and effective for various manifestations of Behçet's disease; often it is used in combination with corticosteroids.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1984        PMID: 6373632     DOI: 10.1111/j.1365-4362.1984.tb05658.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  8 in total

1.  Pathergy.

Authors:  Vishal Madan; John Lear
Journal:  CMAJ       Date:  2007-04-24       Impact factor: 8.262

2.  Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon.

Authors:  D Tsambaos; D Eichelberg; M Goos
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

3.  Long-term progression of retinal vasculitis in Behçet patients using a fluorescein angiography scoring system.

Authors:  Hae Min Kang; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-07       Impact factor: 3.117

4.  Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement.

Authors:  Masaru Takeuchi; Hideyuki Hokama; Rintaroh Tsukahara; Takeshi Kezuka; Hiroshi Goto; Jun-Ichi Sakai; Masahiko Usui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-28       Impact factor: 3.117

5.  Analysis of Th Cell-related Cytokine Production in Behçet Disease Patients with Uveitis Before and After Infliximab Treatment.

Authors:  Masaru Takeuchi; Yoko Karasawa; Kohzou Harimoto; Atsushi Tanaka; Masaki Shibata; Tomohito Sato; Rachel R Caspi; Masataka Ito
Journal:  Ocul Immunol Inflamm       Date:  2016-04-12       Impact factor: 3.070

6.  Aortic valve involvement in Behçet's disease. A clinical study of 9 patients.

Authors:  Choong Won Lee; Jisoo Lee; Won Ki Lee; Chan Hee Lee; Chang Hee Suh; Chang Ho Song; Yong Beom Park; Soo Kon Lee; Yong Soon Won
Journal:  Korean J Intern Med       Date:  2002-03       Impact factor: 2.884

Review 7.  Update on the Medical Management of Gastrointestinal Behçet's Disease.

Authors:  Giuseppe Lopalco; Donato Rigante; Vincenzo Venerito; Claudia Fabiani; Rossella Franceschini; Michele Barone; Giovanni Lapadula; Mauro Galeazzi; Bruno Frediani; Florenzo Iannone; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2017-01-22       Impact factor: 4.711

8.  Onyx Embolization of Ruptured Intracranial Aneurysm Associated with Behçet's Disease.

Authors:  Maher Kurdi; Saleh Baeesa; Mohammed Bin-Mahfoodh; Khalil Kurdi
Journal:  Case Rep Vasc Med       Date:  2013-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.